Alzheimer’s Disease is the most common cause of dementia that is primarily a disease of the elderly with accelerating prevalence after the age of 65. With aging of the global population estimates are that the number of people with AD will exceed 150 million by 2050. The economic and emotional burdens of this disease for both patients and care givers are difficult to overstate. This panel will discuss the current state of diagnosis, monitoring and treatment of the disease, pharmacological approaches to treat the disease itself and approaches to slow symptom progression. This will include updates on what has been seen thus far from the recent approval of monoclonal antibodies that target amyloid, lecanemab/Leqembi and donanemab/Kisunla, and prospects for disease diagnosis using blood-based biomarkers with the ultimate goal of replacing PET scans and lumbar punctures to confirm amyloid positivity. In addition, the panel will discuss pipeline opportunities including next-generation anti-amyloid antibodies like Roche’s trontinemab, Lilly’s remternetug, and anti-tau agents like Biogen’s BIIB080.